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Abstract
Lrp4 is a multifunctional member of the low density lipoprotein-receptor gene family and a modulator of extracellular cell
signaling pathways in development. For example, Lrp4 binds Wise, a secreted Wnt modulator and BMP antagonist. Lrp4
shares structural elements within the extracellular ligand binding domain with Lrp5 and Lrp6, two established Wnt co-
receptors with important roles in osteogenesis. Sclerostin is a potent osteocyte secreted inhibitor of bone formation that
directly binds Lrp5 and Lrp6 and modulates both BMP and Wnt signaling. The anti-osteogenic effect of sclerostin is thought
to be mediated mainly by inhibition of Wnt signaling through Lrp5/6 within osteoblasts. Dickkopf1 (Dkk1) is another potent
soluble Wnt inhibitor that binds to Lrp5 and Lrp6, can displace Lrp5-bound sclerostin and is itself regulated by BMPs. In a
recent genome-wide association study of bone mineral density a significant modifier locus was detected near the SOST
gene at 17q21, which encodes sclerostin. In addition, nonsynonymous SNPs in the LRP4 gene were suggestively associated
with bone mineral density. Here we show that Lrp4 is expressed in bone and cultured osteoblasts and binds Dkk1 and
sclerostin in vitro. MicroCT analysis of Lrp4 deficient mutant mice revealed shortened total femur length, reduced cortical
femoral perimeter, and reduced total femur bone mineral content (BMC) and bone mineral density (BMD). Lumbar spine
trabecular bone volume per total volume (BV/TV) was significantly reduced in the mutants and the serum and urinary bone
turnover markers alkaline phosphatase, osteocalcin and desoxypyridinoline were increased. We conclude that Lrp4 is a
novel osteoblast expressed Dkk1 and sclerostin receptor with a physiological role in the regulation of bone growth and
turnover, which is likely mediated through its function as an integrator of Wnt and BMP signaling pathways.
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Introduction
Osteoporosis and the inherently increased susceptibility to
sustain fractures associated with this disease represent a major
challenge in our aging western societies. Bone mineral density
(BMD) is used as a reference to diagnose and to monitor
osteoporosis and is the best predictor of fractures and a valuable
tool for fracture risk assessment [1,2]. Although much progress has
been made in the molecular understanding of bone metabolism in
recent years, no therapy is yet available to cure osteoporosis [3].
Many of the current approaches to identify potential therapeutic
targets are focused on the Wnt/b-catenin signaling pathway,
which is of fundamental importance for osteogenesis [4–6]. In a
recent genome-wide association study of BMD in individuals of
European descent, a new locus was identified near the SOST gene
at 17q21, which encodes for the osteocyte secreted protein
sclerostin [7], a potent inhibitor of bone formation. Within the
same study, nonsynonymous SNPs in the LRP4 gene at 11p11
were suggestively associated with bone density (BMD) [7],
confirming previous findings of another study from the same
group in which non-significant association of SNPs within or close
to the LRP4 locus with BMD and fractures had been reported [8].
Sclerostin functions as a secreted antagonist of both the bone
morphogenetic protein (BMP) [9,10] and Wnt signaling pathways
[11,12] and Lrp4 has been proposed to function as an integrator of
BMP and Wnt signaling [13]. However, whether sclerostin and
Lrp4 bind physically to each other, or whether they form an
indirect functional interaction has not been known.
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7930Lrp4 is a member of the multifunctional low-density lipoprotein
receptor (Lldlr) gene family [14–16]. Physiological functions for
this ancient gene family include the endocytosis of a large number
of macromolecules, including lipoproteins, proteases and protease
inhibitors, as well as functions as direct signal transducers or
modulators of several fundamental signal transduction pathways,
including BMP, TGFb, PDGF, reelin and canonical Wnt
signaling.
Insight into the physiological functions of Lrp4 has been gained
through naturally occurring or genetically engineered mutations in
mice and cattle. Lrp4 is expressed in various organs [17–19], as
well as in bone (this study). Mice bearing functional Lrp4 null
mutations die perinatally due to a failure of forming neuromus-
cular junctions [20–22]. In addition, limb development is also
abnormal [18,20]. Hypomorphic mutations of the Lrp4 gene are
compatible with survival and present with a variable degree of
skeletal abnormalities, in particular fusion of digits at the hind and
fore limbs (polysyndactyly). By engineering a stop codon just
upstream of the transmembrane domain of the murine Lrp4 gene,
we have generated such a hypomorphic dysfunctional receptor
(Lrp4 ECD), in which the lack of a membrane anchor prevents the
efficient interaction of Lrp4 with its extracellular ligands. Animals
carrying this mutation are viable but present with growth
retardation, polysyndactyly and tooth developmental abnormali-
ties [13,18]. A similar polysyndactyly phenotype has been
observed also with other allelic mutations in the murine [23]
and bovine [24] Lrp4 gene. It was recently shown that Lrp4
integrates BMP and Wnt signaling during tooth development by
binding the BMP antagonist Wise [13]. The role of Lrp4 as an
antagonist of canonical Wnt signaling pathway is thought to be
mediated in part by a displacement of the homologous Lrp5/6
proteins in the co-receptor complex formed by frizzled proteins
(fzd) with Lrp5/6, which is required to bind Wnt proteins and to
transduce the Wnt signal to downstream elements of the canonical
cascade.
Lrp5/6 are established Wnt co-receptors with important roles in
osteogenesis. Gain of function and loss of function mutations in the
Lrp5 gene lead to a high bone mass and low bone mass phenotype,
respectively, both in mice and humans (for review, see [25]).
Mutations in the Lrp6 gene display a partially overlapping bone
phenotype with the various Lrp5 mutations (for review, see [26]).
Sclerostin is a potent osteocyte secreted inhibitor of bone
formation that directly binds to Lrp5 and Lrp6 [12,27]. The
powerful anti-osteogenic effect of sclerostin is thought to be
mediated mainly by inhibition of Wnt-signaling through Lrp5/6
within osteoblasts by disrupting the Wnt induced frizzled/Lrp
complex formation, although sclerostin was first found to inhibit
not Wnt, but the action of murine and human BMPs in vitro [9,10].
Sclerostin is predominantly expressed in skeletal tissues [9,10].
Mutations in SOST cause the human disease sclerosteosis, which
is characterized by massive bone overgrowth [28,29]. Van
Buchem’s disease is a similar disorder with generalized hyperos-
tosis and a 52-kb deletion downstream (35 kb) of the SOST gene
that removes a SOST-specific regulatory element [30,31].
Consistent with a function of sclerostin as an inhibitor of bone
formation, transgenic mice overexpressing human SOST, display a
low bone mass phenotype [10,32] and Sost knockout mice have
higher bone mass with increased BMD and bone strength [33].
Interestingly, overexpression of human SOST in transgenic mice
resulted in an additional phenotype with fused or missing digits of
the fore and hind limbs, reminiscent of the phenotype of mice with
dysfunctional Lrp4 [32].
Dickkopf1 (Dkk1) is another soluble inhibitor of Wnt/b-catenin
signaling that binds to Lrp5 and Lrp6 [34–37]. Dkk1 is required
for embryonic head and limb development. It also regulates
postnatal bone accretion and maintenance of bone mass mainly by
binding to Lrp5/6 in a process that involves the transmembrane
proteins Kremen 1 or Kremen 2 [34,38], although at least some of
the Wnt-inhibitory effects of Dkk1 mediated by Lrp5/6 seem to be
independent of Kremen [39]. Dkk1 null mice die perinatally and
show severe developmental phenotypes, including head and limb
dysmorphogenesis [40]. A transgenic mouse mutant with reduced
Dkk1 expression displays postnatal polysyndactyly, which can be
partially rescued by the concomitantly reduced expression of
Lrp5/6 [41]. Overexpression of Dkk1 in osteoblasts causes
osteopenia [42] and Lrp5 mutants that cannot bind Dkk1 show
increased bone mass both in mice and in humans [37,43]. Dkk1
binds to the first EGF-like domain of Lrp5/6, with which also
sclerostin and Wnts interact [34,44]. It has been shown that Dkk1
can displace sclerostin from the Lrp5 sclerostin complex [45].
Moreover, the expression of Dkk1 has been reported to be
regulated by BMPs [46].
The current study was prompted by the association of both the
SOST and the LRP4 gene with BMD [7,8,47,48] the established
function of both Sost and Lrp4 in the modulation of BMP and
Wnt signaling [13,49,50], the partially overlapping developmental
phenotypes in genetically manipulated mice of the Sost, the Dkk1
and the Lrp4 genes, and our previous findings that Lrp4 binds
Wise (a.k.a. Sostdc1) through its extracellular domain which is
homologous to that of Lrp5/6 which interacts with sclerostin and
Dkk1.
Here, we have used in vitro and in vivo analysis of wild type
mice and of two Lrp4 mutant mouse strains, one fully deficient
(null mutant, Lrp4-/-; Dietrich et al., in preparation) and a
functional hypomorph (Lrp4-ECD; [18]) to show that Lrp4 is an
osteoblast expressed receptor for Dkk1 and sclerostin and regulates
bone growth and bone turnover in vivo.
Materials and Methods
Ethics Statement
All animal work has been conducted according to relevant
national and international guidelines. In accordance with the
recommendations of the Weatherall report, ‘‘The use of non-
human primates in research.’’ the following statement to this effect
has been included to document the details of animal welfare and
steps taken to ameliorate suffering in all work involving non-
human primates: This work has been reviewed and approved by
the Institutional Animal Care and Use Committee at the
University of Texas Southwestern Medical Center (IACUC). This
committee functions in close cooperation with the Association for
Assessment and Accreditation of Laboratory Animal Care
International (AAALAC). The performance site for this work
(UT Southwestern) is an AAALAC accredited institution.
Production of Recombinant Proteins and Binding Assay
HEK293A cells were transfected with pCDNA3-AP, pCDNA3-
RAP-AP, pCDNA3-Wise-AP, pCDNA3-RSpondin2-AP, pCDNA3-
DKK1-AP, or pCDNA3-SOST-AP constructs using FuGENE 6
(Roche) in DMEM plus 0.2% BSA medium to produce conditioned
media containing AP or AP-tagged recombinant proteins. After 48 h
transfection, media were collected and the production levels of AP
and AP-tagged proteins in the media were determined by AP activity
assay using p-Nitrophenyl phosphate (Calbiochem) as a substrate. To
investigate the binding of AP-tagged proteins to Lrp4 in a cell-free
system, media containing of the Lrp4 ectodomain fused to the
constant region of Immunoglobulin G (Lrp4ecto-Fc) was produced
by transfection of HEK293A cells with pcDNA3-LRP4ecto-Fc in
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LRP4ecto-Fc was incubated with Protein A-Agarose beads (Sigma)
at 4uC for 2 h to bind LRP4ecto to the beads. Equal volumes of
media containing AP or AP-tagged proteins were pre-cleared with
Protein A-Agarose beads at 4uC for 2 h and then incubated with the
LRP4ecto-bead conjugates at 4uC overnight. The conjugates were
washed four times with PBS, resuspended in 40 ml Laemmli sample
buffer, and western blotting was performed using anti-AP antibody
(Sigma). To investigate binding of AP-tagged proteins to LRP4 in cell
system, HEK293A cells were transfected with pCDNA3-LRP4 full
length constructs for 48h, washed once with PBS plus 0.1% BSA, and
incubated in equal volumes of media containing AP or AP-tagged
proteins at 37uC for 1 h. The cells were washed once with PBS,
incubated with the cross-linker dithiobis[succinimidylpropionate]
(250 mM, Pierce), at room temperature for 30 min, harvested,
washed three times with PBS, and lysed in 50 mM Tris-HCl buffer,
pH 7.5 containing 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2,1 %
Triton X-100, and protease inhibitors (Roche). After determination
of protein concentration by Lowry assay, equal protein amounts of
the cell lysates were subjected to immunoprecipitation using anti-AP
antibody and Protein A-Agarose beads. Immunoprecipitates were
boiled in SDS sample buffer containing 5% b-mercaptoethanol and
western blotting was performed using anti-Lrp4 antibodies derived
against the carboxy terminus and the murine Lrp4 ectodomain,
respectively.
Animals
Lrp4ECD mice were generated by introducing a stop codon
into the exon 36 of Lrp4 gene, resulting in the extracellular
truncation of the protein and the loss of the transmembrane and
intracellular domains of LRP4 [18]. To minimize the effects of
genetic drift and vertical inbreeding, mice from the entire
Lrp4ECD heterozygote pool of our colony on a 129SvEv x
C57BL/6 hybrid background were crossed to produce wild type
and Lrp4ECD littermate controls. All animals were maintained in
the UT Southwestern animal facility with 12h light/12 h dark
cycle and fed a standard rodent chow diet (Diet 7001, Harlan
Teklad, Madison, WI) with access to water ad libitum. At ten weeks,
experimental mice were fasted for 4 h prior to collection of urine.
After urine collection, the mice were euthanized with isoflurane
prior to collection of blood followed by harvesting of the calvaria,
lumbar spine, and femur. All procedures were performed in
accordance with the protocols approved by the Institutional
Committee for Use and Care of Laboratory Animals of the
University of Texas Southwestern Medical Center at Dallas
(IACUC).
Determination of LRP4 Expression in Bones and
Osteoblasts
Calvaria and femur were cleaned by removing soft tissues
connected with scalpel and snap-frozen in liquid nitrogen for
storage until the extraction of protein and RNA. Primary
osteoblasts were obtained by sequential collagenase digestion of
calvariae from 3–4 day old wildtype C57Bl/6 mice as described
[52].Osteoblast differentiation was induced at 80% confluency in
aMEM containing 10% fetal bovine serum, 50 mg/ml ascorbic
acid and 10 mM b-glyerophosphate. At day six of differentiation,
total cell proteins were isolated and subject to western blot
analysis. To extract bone proteins, calvaria and femur were
ground in a mortar in liquid nitrogen followed by sonication in
50 mM Tris-HCl buffer, pH 7.5 containing 150 mM NaCl,
1 mM MgCl2, 1 mM CaCl2, 1% Triton X-100, and protease
inhibitors (Roche). After determination of protein concentration
according to Lowry, the extracted bone proteins were subjected to
western blotting with anti-LRP4 antibodies along with brain
proteins from wildtype and from Lrp4 null mice as positive and
negative controls, respectively.
Total RNA from calvaria and femur was extracted in RNA
STAT-60 (Tel-Test Inc.) using a Polytron homogenizer. The RNA
was treated with DNase I (Ambion Inc.) to exclude potential
contamination by DNA. Two mg of DNA-free RNA were reverse-
transcribed using TaqMan Reverse Transcription Reagents
(Applied Biosystems). Quantitative real-time PCR analysis was
performed using the ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems). Each 20 ml reaction contained
20 ng/ml cDNA, 2.5 mM forward and reverse primers, and 10 ml
of 2x SYBR Green PCR Mater Mix (Applied Biosystems). All
samples were run in triplicates and specific amplification of a single
PCR product with the expected length was confirmed with gel
electrophoresis. The following primers were used:
LRP4, 59-TCTGCGCACACGGAATAGC (forward),
59-GCGCTCACCGCACATGT (reverse);
36B4, 59-CACTGGTCTAGGACCCGAGAAG (forward),
59-GGTGCCTCTGGAGATTTTCG (reverse).
mCT analysis of Bone
The femoral and spinal bones of mouse were scanned at an
isotropic voxel size of 27 mm (80 kV, 450 mA and 2000 ms
integration time) using the eXplore Locus micro-CT scanner (GE
Health Care). The scan was done transversely which generated
720 tomographic slices from a 33 mm sample depth. Three
dimensional images were then reconstructed from these two-
dimensional gray-scale image slices using the reconstruction utility
(GE Medical System) and visualized using Microview Software
(GE Medical System). Density values for soft tissue and bone were
calibrated using a phantom (GE Health Care) containing air
bubble, water and hydroxyl apatite rod. The region of interest
(ROI) for each animal tissue was defined based on skeletal
landmarks from the grey-scale images.
Bone analysis was conducted using Microview software. For
femoral analysis, bone mineral density (BMD) and bone mineral
content (BMC) were measured in cortical bones. For determina-
tion of cortical bone, an appropriate ROI (region of interest) was
defined and the histogram was created on this selected region. The
separation of cortical region was calculated from the grey scale
values (upper threshold 4300 and lower threshold 900) on the
histogram. BMD, BMC and trabecular structural measurement in
vertebral bone was done by Microview using the threshold selected
for trabecular bone (upper threshold 1400 and lower threshold
600). Data analysis and calculations were automatically performed
by the software. All mCT analyses were done with samples in a
randomly selected sequence by an independent blinded investiga-
tor who did not know the study hypothesis.
Measurement of Bone Formation and Resorption Markers
All serum and urine samples had been stored at minus 70uC
immediately after the blood draw and were not unfrozen prior to
analysis. Serum levels of osteocalcin were measured using a two-site
immunoradiometric assay (Immutopics) according to the manufac-
turer’s instructions. Alkaline phosphatase activity in serum, was
measured using the pNPP method. Briefly, 5 ml of serum were
mixed with 50 ml of substrate solution containing 2 mg/ml of p-
Nitrophenyl Phosphate (Sigma) in alkaline buffer solution (Sigma).
After incubation at 37uC for 15 min, the reaction was stopped by
adding 500 ml of 0.5M NaOH and the absorbance at 405 nm was
measured. Alkaline phosphataseactivity was determinedbyusing p-
nitrophenol solution (Sigma) as standard substrate.
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deoxypyridinoline (DPD) using MicroVue DPD (Quidel) accord-
ing to the manufacturer’s instructions. The DPD values were
normalized to the levels of urinary creatinine measured using the
MicroVue Creatinine Assay Kit (Quidel).
Results
Lrp4 Interacts with Dkk1 and Sclerostin In Vitro
Both Dkk1 and sclerostin modulate Wnt signaling by binding to
EGF-like repeats of Lrp5 and Lrp6. The extracellular domains of
Lrp5, Lrp6 and Lrp4 are highly conserved [18], raising the
possibility that the spectrum of ligands that bind to Lrp5/6 and
Lrp4 might overlap. In order to test for a physical interaction
between Dkk1 and Lrp4 as well as sclerostin and Lrp4, we
performed two types of in vitro binding assays. First, HEK293A
cells transfected with Lrp4 were incubated with conditioned media
containing the alkaline phosphatase (AP)-tagged putative Lrp4
ligands (Figure 1A). The 39kDa receptor-associated protein (RAP),
a chaperone for Ldlr gene family members, is known to bind to
Lrp4 [51]. We have previously shown that Wise interacts with
Lrp4, while another modulator of the Wnt signalling pathway, R-
spondin2 (RS2) does not [13]. Thus, RAP and Wise served as
positive controls, RS2 and non-tagged AP as negative controls for
these assays. AP-fusion proteins of controls and the putative
ligands Dkk1 and sclerostin were pulled down with an antibody
against AP and immunoblotted with an anti-Lrp4 antibody to
detect co-precipitated receptor (Figure 1B). In a complementary,
converse cell free assay, the Lrp4-Fc fusion protein was
immobilized on Protein A-agarose and incubated with the AP-
tagged putative ligands and controls. Lrp4 bound ligands were
then detected by immunoblotting against AP (Figure 1C). Both
assays revealed that Lrp4 efficiently binds Dkk1 and sclerostin.
Lrp4 is Expressed in Osteoblasts
Sclerostin is a secreted protein expressed by osteocytes. Both
sclerostin and Dkk1 bind to Lrp5/6, which play critical roles in the
Wnt/b-catenin signal transduction in osteoblasts. The inhibition of
bone formation by Dkk1 and sclerostin is thought to be mediated
primarily through inhibition of wnt-signaling in osteoblasts. In light
of our finding that Dkk1 and sclerostin bind to Lrp4 (Figure 1), we
next analyzed whether Lrp4 is expressed in bone. Figure 2A-C and
Table 1 demonstrate by quantitative RT-PCR and Western blot
analysis that Lrp4 mRNA and protein are indeed expressed in
calvaria and in the long bones of adult wild type mice. Murine
embryonic brain (E18) from Lrp4 null mice and wild type
littermates served as a negative and positive control for the RT-
PCR and immunoblots, respectively (Figure 2A, B). Moreover, a
polyclonal antibody derived against the recombinantly expressed
Lrp4 ligand binding domain specifically recognizes Lrp4 in brain
protein extracts (Figure 2B). In Lrp4 null animals, in which the
promoter and exon 1 of Lrp4 have been deleted (Dietrich et al., in
preparation) neither mRNA (Figure 2A, Table 1), nor Lrp4 protein
was detectable (Figure 2B), whereas mRNA and protein were
present in wild type calvaria, femur (Figure 2A, B) and primary
calvarial osteoblasts from newborn wild type mice that had
undergone six days of in vitro differen>tiation with ascorbate and
b-glycerolphosphate (Figure 2C). Taken together, these data
demonstrate that Lrp4 is expressed by osteoblasts in murine bone.
Functional Lrp4 Deficiency Results in Impaired Skeletal
Growth, Reduced Trabecular Bone Volume and Increased
Bone Turnover
To investigate the physiological significance of the expression of
Lrp4 by osteoblasts, we performed micro computer tomography
(mCT) of the femur and lumbar spine vertebrae of Lrp4ECD
mutant mice and wild type littermates. We also measured several
biochemical markers that are indicative of bone turnover. Ten week
old male animals were analyzed (n=6 per genotype for mCT, and
n=14 per genotype for the determination of turnover markers).
Fasting blood and urine samples were obtained before sacrifice
accordingtoastandardizedtimescheduletoruleoutanypotentially
confounding circadian alterations in the concentrations of the
osteoblast activity markers alkaline phosphatase (ALP) and
osteocalcin (OCN) as well as the urinary collagen breakdown
product desoxypyridinoline (DPD) as a marker of osteoclast activity.
Body weight of the animals was determined upon sacrifice. Ten
week old wildtype mice had a significantly higher total body weight
(25.7 +/2 1.3 g) than their Lrp4ECD littermates (20.3 +/2 1.4 g)
(Figure 3B), consistent with our earlier findings [18]. Polysyndactly
of fore limbs and hind limbs and abnormal tooth development are
fully penetrant [18]. MicroCT 3D and 2D reconstruction of the
Figure 1. Dkk1 and sclerostin bind to Lrp4. Panel A, HEK293A cells
were transfected with alkaline phosphatase (AP) as a control and with
AP-tagged confirmed and putative Lrp4 ligands. The relative abun-
dance of the respective ligands in the cell culture supernatant is shown
as AP activity (arbitrary units). Panel B, Conditioned media containing
the indicated AP-fusion proteins were incubated with HEK293A cells
overexpressing Lrp4. After binding and crosslinking, AP-fusion proteins
were immunoprecipitated, and coprecipitated LRP4 was detected by
immunoblotting. RAP constitutively interacts with LDL receptor family
members and serves as a positive control. R-spondin2 served as a
negative control. LRP4 coprecipitates with Dkk1 and sclerostin AP-
fusion proteins. Panel C, In a cell free assay, soluble Lrp4 ectodomain-Fc
fusion protein was conjugated to Protein A-Agarose, incubated with
media containing the AP-tagged putative Lrp4 ligands and Lrp4 bound
ligands were then detected by immunoblotting against AP.
doi:10.1371/journal.pone.0007930.g001
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of the bones(Figure 3A), butshowedthat thereductionoftotal body
weight was accompanied by a significant reduction of femur length
(13.5 +/2 0.3 mm vs 12.5 +/2 0.2 mm p=0.0001) and a clear,
albeit statistically non-significant trend towards a reduction in the
combined height of lumbar vertebrae L3 and L4 (6.36 +/2
0.36 mm vs 5.78 +/2 0.58) of Lrp4ECD mutants as compared to
controls (Figure 3B and 4B). Furthermore, the inner and outer
cortical perimeter of the femur mid-diaphyses was significantly
smaller in Lrp4ECD mutants (Figure 3B, p,0.0001 and p=0.002).
These findings indicate that at least part of the reduction of the total
body weight was due to impaired skeletal growth. This is consistent
with our previous report of a role of Lrp4 as a modulator of the
BMP and Wnt signaling cascades in limb and tooth development,
since both pathways also play a role in the enchondral ossification
process in the growth plate that controls limb length growth. Total
femur bone mineral content (BMC) and bone mineral density
(BMD) were also significantly reduced in Lrp4ECD mutants (BMC
11.1 +/21.3 mg versus 9.0 +/2 1.5 mg, p,0.05 and BMD 641.3
+/2 16.7 mg/cc versus 602.3 +/2 21.4 mg/cc, p,0.01), while
cortical thickness, cortical BMC and cortical BMD were unaffected
(Figure 3B), suggesting that the difference in total femur BMD/
BMC was due to differences in the trabecular compartment of the
femur. For the assessment of trabecular bone structure and density
in mice, the lumbar spineis bettersuited than the distal femuror the
proximal tibia. We therefore performed mCT on the lumbar
vertebrae L3 and L4. Again, 3D and 2D reconstructions did not
unveil gross abnormalities of lumbar spine morphology (Figure 4A),
but trabecular bone analyses revealed a significantly reduced bone
volume per total volume (BV/TV, 18.9 +/2 1.5% vs 15.7 +/2
2.5%) in Lrp4 ECD mutants as compared to wild type littermates,
accompaniedbythe accordingchangesintrabecularseparationand
trabecular number (Figure 4B). Trabecular thickness was not
significantly affected (Figure 4B). Taken together, mCT analyses of
the femur and lumbar spine indicate impaired bone growth in
Lrp4ECD mutant mice, with smaller bones of otherwise mostly
normal morphology and suggest a concomitant relative increase of
bone resorption over bone formation, resulting in a net loss of
trabecular bone.
To further explore the underlying cause of this phenotype, we
measured the osteoblast activity markers osteocalcin (OCN,
Figure 5A) and alkaline phosphatase (ALP, Figure 5B) in serum
and urinary deoxypyridinoline (DPD) as an osteoclast activity
marker (Figure 5C). All parameters were significantly elevated in
the Lrp4ECD mutants (OCN: 15.1 +/21.9 ng/ml vs 22.0 +/2
3.9 ng/ml; ALP: 230.2 +/2 22.3 units/ml vs 365.5 +/2
41.1 units/ml; DPD/creatinine: 9.3 +/2 1.9 nmol/mmol vs
11.4 +/2 2.4 nmol/mmol), indicating increased bone turnover
in comparison to wild type control animals.
Discussion
Here we report that Lrp4 binds the two secreted Wnt
modulators Dkk1 and sclerostin, that Lrp4 is expressed by murine
Figure 2. Lrp4 is expressed in bone. Panel A, Agarose gel of the PCR products from the experiment shown in the Table. Panel B, Extracted
proteins were subjected to immunoblotting with an antibody against LRP4. Panel C, Protein extracts from primary osteoblast cultures after 6 days of
in vitro differentiation were subjected to anti-LRP4 immunoblotting. Brain and calvarial extracts are shown as controls.
doi:10.1371/journal.pone.0007930.g002
Table 1. Lrp4 is expressed in bone.
Gene
WT E18
Brain Ct
(avg.6 6S.D.)
Lrp4-/- E18
Brain Ct
(avg.6 6S.D.)
WT adult
calvaria Ct
(avg.6 6S.D.)
WT adult
femur Ct
(avg.6 6S.D.)
Lrp4 27.960.06 N.D. 28.860.10 31.360.21
36B4 20.760.02 21.060.01 24.460.01 25.960.03
Total RNA was extracted from embryonic brain (E18), calvaria and femur cortical
bone of 10-week-old adult mice. Quantification of Lrp4 and control (36B4)
mRNA was performed by real-time PCR. Results represent the average of cycle
threshold (Ct)6S.D. in triplicate.
doi:10.1371/journal.pone.0007930.t001
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functionally hypomorphic Lrp4 mutation have impaired bone
growth and increased bone turnover.
Canonical Wnt-signaling is of crucial importance for osteogen-
esis and has probably been the most intensely studied signaling
pathway in bone in recent years. Lrp5 and Lrp6 have been
recognized as the main osteoblast expressed co-receptors of the
frizzled family of proteins, which together form a receptor
complex at the cell surface that binds the Wnt signaling proteins
and thereby initiates the canonical signaling cascade. The finding
that Lrp4 is also expressed by osteoblasts in bone has important
implications for the understanding of the complexity of the
Figure 3. Lrp4ECD results in impaired bone growth. Panel A, Representative mCT images of WT and Lrp4ECD mouse femurs. Panel B, Total body
weight of ten week old male mice was determined prior to sacrifice. Spinal column and femurs were dissected out, fixed in 4% paraformaldehyde and
scanned. Calculations for the indicated parameters were performed using Microview software from GE Medical System. Results represent the
average6S.E. of values from six male mice.
doi:10.1371/journal.pone.0007930.g003
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Sclerostin and Dkk1 are inhibitory modulators of the Wnt/b-
catenin pathway and it has been generally assumed that these
molecules exert their antagonistic effect mainly through direct
binding to Lrp5/6, thereby blocking binding sites on these
receptors for the pathway activating Wnts. Here we have shown
that Lrp4 efficiently binds both sclerostin and Dkk1, suggesting
that at the osteoblast surface, Lrp4 could either compete with
Figure 4. Lumbar spine trabecular bone is reduced in Lrp4ECD mice. Panel A, Representative mCT images of wild type and LRP4ECD mouse
lumbar vertebra L3 and L4. Panel B, Lumbar vertebrae were fixed, scanned, and analyzed for the indicated parameters. Results represent the
average6S.E. of values from six male mice.
doi:10.1371/journal.pone.0007930.g004
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with the Lrp5/6/frizzled co-receptor complex by binding and
presenting these ligands to Lrp5/6. LRP4, but not Lrp5/6, contains
an NPXY endocytosis motif in its cytoplasmic domain. However, it
is not known whether Lrp4 contributes to the endocytosis of
extracellular molecules to a significant extent. The exact nature of
both the cellular consequences of sclerostin and Dkk1 binding to
Lrp4 as well as the impact that this process may have on the
signaling function of Lrp5/6 in bone and other tissues will have to
be determined by future studies. It is likely that mouse genetics with
double and triple knockout combinations of receptor and ligand
genes will be needed to fully understand these interactions.
How can we explain the bone phenotype of Lrp4ECD mice?
We have previously shown that Lrp4 integrates BMP and Wnt
signals in tooth development in mice [13] by binding Wise, a
secreted BMP antagonist that also binds to Lrp6 and thereby
inhibits Wnt signaling. In analogy to Wise, sclerostin and Dkk1 are
two other Lrp5/6 ligands that we have now shown to also interact
with Lrp4. One possible mechanism is that Lrp4 simply acts as a
sink and competes with Lrp5/6 for the binding of these Wnt
antagonists, which then are no longer available for suppression of
the signal through the Lrp5/6 axis. When Lrp4 is dysfunctional as
in the Lrp4ECD mutant strain that we used here, the availability
of extracellular Wnt- antagonists increases, resulting in a net
inhibitory effect on canonical Wnt/b-catenin signaling in the cell,
which is well known to decrease BMD and thus would provide an
explanation for the reduced lumbar spine trabecular BV/TV in
the Lrp4ECD mutant mice. Furthermore, both Wnt signaling and
BMP signaling are involved in the growth plate organization and
enchondral ossification process [53–56]. Moreover, Lrp4 can by
itself inhibit Wnt signaling, presumably by competing for Lrp5/6
in the Wnt/Fz complex [18]. Since sclerostin can inhibit BMPs,
and Dkk1 is itself regulated by BMPs, it is likely that the failure to
properly integrate BMP and Wnt signaling pathways in the
absence of a normal, functional Lrp4 is responsible for the reduced
limb length growth in the Lrp4 ECD mutants. Such a mechanism
would be analogous to the role of LRP1 in the integration of
PDGF and TGFb signals in the vascular wall, where loss of LRP1
expression in smooth muscle cells results in the simultaneous
deregulation of PDGF as well as TGFb signalling with medial
hypertrophy, elastolysis and fibrosis [57–59].
The elevated concentration of biochemical bone turnover
markers, serum osteocalcin, alkaline phosphatase and urinary
DPD in Lrp4ECD animals indicate that both osteoblast and
osteoclast activities are significantly increased in these mice. This
could be either explained by an altered coupling of osteoblast and
osteoclast activity due to osteoblast-specific changes in Wnt and
BMP signaling, or by altered osteoclast function independent of
osteoblasts. We failed to detect Lrp4 expression in primary
osteoclast cultures from wildtype mice (data not shown), which
would favour a mechanism in which altered coupling leads to
increased osteoclast activity in this mouse model, possibly by a
mechanism similar to the one observed in mutant mice with
osteoblast-specific inactivation of b-catenin which results in
increased bone resorption [60]. In addition to its role as a bone
formation marker, the osteoblast-specific protein osteocalcin has
been shown to regulate glucose metabolism and fat mass in mice
[61]. Whether the elevated concentrations of osteocalcin in
Lrp4ECD mice are also associated with an altered glucose
metabolism will have to be determined.
The current study cannot distinguish whether the observed
bone phenotype of the Lrp4ECD mutant is due to an impaired
interaction of osteoblast expressed Lrp4 with Dkk1, with sclerostin,
or most likely with both proteins. Future studies will have to
address to what degree the phenotype is synthetic, e.g. by
analyzing mice with osteoblast-specific inactivation of Lrp4 in
combination with mutations in Dkk1 and sclerostin.
Figure 5. Bone turnover markers are increased in Lrp4ECD.
Urine and blood samples were collected from the same mice that were
used for analyses in Figure 3 and 4. Panel A, The bone formation
markers osteocalcin and alkaline phosphatase were determined in
serum. (B) Urinary levels of DPD/creatinine were measured as a marker
for bone resorption.
doi:10.1371/journal.pone.0007930.g005
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PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e7930In conclusion, the expression of Lrp4 by osteoblasts described
here adds another player to the long list of established factors that
modulate canonical Wnt signaling in bone. By demonstrating that
in addition to Wise, Lrp4 is able to interact with two additional
important modulators of Wnt and BMP signaling, our perspective
of the complexity of the integration of BMP and Wnt signaling
pathways on the osteoblast surface has expanded further.
Extensive further studies are clearly necessary to fully understand
the mechanisms by which Lrp4 deficiency leads to impaired bone
growth, increased bone turnover and polysyndactly in these
mutant mice. Nevertheless the recently described association of
both the SOST and LRP4 genes with BMD in humans, together
with our findings suggest that LRP4 plays a physiologically
important role in the skeletal development and bone metabolism
not only in rodents, but in humans as well.
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